Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  T. Whiteside,et al.  Circulating Exosomes Carrying an Immunosuppressive Cargo Interfere with Adoptive Cell Therapy in Acute Myeloid Leukemia , 2016 .

[3]  H. Ljunggren,et al.  Emerging insights into natural killer cells in human peripheral tissues , 2016, Nature Reviews Immunology.

[4]  H. Klingemann,et al.  Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells , 2016, Front. Immunol..

[5]  W. Wels,et al.  NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[6]  R. Childs,et al.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens , 2015, Nature Reviews Drug Discovery.

[7]  Bin Zhang,et al.  Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. , 2014, Blood.

[8]  Jeffrey S. Miller,et al.  Clinical utility of natural killer cells in cancer therapy and transplantation. , 2014, Seminars in immunology.

[9]  Jeffrey S. Miller.  Therapeutic applications: natural killer cells in the clinic. , 2013, Hematology. American Society of Hematology. Education Program.

[10]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[11]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[12]  M. Smyth,et al.  Characterizing the anti-tumor function of adoptively transferred NK cells in vivo , 2010, Cancer Immunology, Immunotherapy.

[13]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Whiteside,et al.  Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors , 2009, Cancer Immunology, Immunotherapy.

[15]  M. Bishop,et al.  Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  H. Klingemann,et al.  Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. , 2008, Cytotherapy.

[17]  M. Martelli,et al.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.

[18]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[19]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Chi-kong Li,et al.  Elevated Serum Interleukin-15 Level in Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation , 2003, Journal of pediatric hematology/oncology.

[21]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[22]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[23]  U. Nannmark,et al.  Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells. , 2000, In vivo.

[24]  P. Steinherz,et al.  Antileukemia activity of a natural killer cell line against human leukemias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  H. Klingemann,et al.  A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  H. Kawasaki,et al.  Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. , 1996, Leukemia.

[27]  J. Gong,et al.  Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. , 1994, Leukemia.